JGH: Tumor burden score can be used as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Hepatocellular carcinoma (HCC) is one of the most common primary liver cancers.
In 2016, 800,000 people worldwide died of HCC
.

Despite improvements in screening programs and treatment methods, the prognosis of HCC is poor, because a very high proportion of patients have large or multiple tumors at the time of onset

 Hepatocellular carcinoma (HCC) is one of the most common primary liver cancers.

 

Researchers performed a retrospective analysis of a total of 935 HCC patients who received TACE in the Taipei Veterans General Hospital
.

Baseline demographic data and clinical variables of all patients, such as the etiology of liver disease, laboratory data, tumor burden (number) and tumor burden (number and size of tumors, vascular infiltration and TBS), liver function reserve, performance status and The Barcelona Clinic Liver Cancer (BCLC) staging is recorded at the time of diagnosis

 

 

The results of the study found that the tumor burden score (TBS) tends to increase as the size and number of tumors in the study patients increase
.

The Cox model showed that serum creatinine ≥ 1.

 

This study confirmed that tumor burden score is a viable new prognostic surrogate for HCC tumor burden, which can well distinguish the survival rates of TACE patients with different baseline characteristics
.

This study confirmed that tumor burden score is a viable new prognostic surrogate for HCC tumor burden, which can well distinguish the survival rates of TACE patients with different baseline characteristics
.

 

 

Original source:

Shu-Yein Ho.

Leave a message here